Myeloma

I explain how the words caregiver and incurable shaped my wife’s cancer journey and why I believe more hopeful language better reflects our experience.

Todd Kennedy, a multiple myeloma survivor, explains how switching from an hours-long IV infusion to a 3-minute Sub-Q injection changed his life.

Stage 2 multiple myeloma can feel overwhelming. Learn what it means, treatment options, and key questions to discuss with your oncologist.

Kimberly Alexander urges care partners to seek support, prioritize self-care and push for better awareness so families in the Black community aren’t overlooked.

The FDA approved Darzalex Faspro for the treatment of adults with high-risk smoldering multiple myeloma.

In October 2025, the FDA granted approval to multiple new cancer therapies and supportive care options, covering treatments across the oncologic landscape.

The FDA approved Blenrep with Velcade and dexamethasone for relapsed or refractory multiple myeloma.

The Food and Drug Administration granted fast track designation to HDP-101 for the treatment of multiple myeloma.

Get the facts on stage 1 multiple myeloma, including why your doctor may recommend active surveillance and what the latest treatment options are.

Thoughts on life, multiple myeloma, architecture and Douglas Adams.

Tamara Mobley shares how persistent back pain led to her myeloma diagnosis and why she now raises awareness to help others recognize subtle warning signs.

A study found that iberdomide with Darzalex and dexamethasone helped more patients with multiple myeloma reach no signs of cancer after treatment.

Tecvayli and Darzalex demonstrated meaningful clinical efficacy in transplant-eligible patients with newly diagnosed multiple myeloma.

What is the first emotion that comes to mind about your cancer journey? For me, the strong emotion that I choose is shock!

Diagnosed with multiple myeloma? Our guide explains each stage and treatment, helping you engage confidently with your care team.

Thoughts on standing up to cancer through recovered mobility and by sharing my multiple myeloma journey.

Data from the AQUILA study support the use of fixed-duration subcutaneous Darzalex Faspro as an early treatment option in high-risk smoldering myeloma.

Through exercise, meditation, and gratitude, I reset my mind and body, finding peace and strength in life after my cancer diagnosis.

Multiple myeloma is a chronic blood cancer affecting plasma cells, but with today’s treatments, many patients can manage symptoms and live fulfilling lives.

The FDA declined approval of Darzalex Faspro for newly diagnosed, transplant-ineligible multiple myeloma in its current form.

Ashley Dieks and Dr. Saad Z. Usmani discussed how bicycling may help patients cope with the emotional and physical challenges of their myeloma diagnosis.

SAR446523, an investigational antibody targeting GPRC5D, received FDA orphan drug status and is in phase 1 trials for relapsed/refractory multiple myeloma.

The FDA's Oncologic Drugs Advisory Committee has casted their votes on the utilization of certain treatments in the multiple myeloma patient population.

The FDA approved Lynozyfic for relapsed multiple myeloma, but serious risks require restricted use under a special safety program.

Label updates have been approved by the FDA for the CAR T-cell therapies Breyanzi and Abecma in large B cell lymphoma and multiple myeloma, respectively.